Визуализация эффекта Т-клеточной терапии с помощью позитронно-эмиссионной томографии при лечении лимфопролиферативных заболеваний, ассоциированных с вирусом Эпштейна–Барр Journal Article


Authors: Dubrovin, M. M.; Dubrovina, E. S.; Likar, Y. N.; Rumyantsev, A. G.
Article Title: Визуализация эффекта Т-клеточной терапии с помощью позитронно-эмиссионной томографии при лечении лимфопролиферативных заболеваний, ассоциированных с вирусом Эпштейна–Барр
Abstract: Viral infections remain a frequent cause of morbidity and mortality in immunosuppressed patients after allogeneic hematopoietic stem cell transplantation. The main infection agents are well known: cytomegalovirus, Epstein-Barr virus (EBV), and adenovirus. Though the overall incidence of EBV-associated post-transplant lymphoproliferative diseases (LPD) is not so high, standard therapy is not always effective. Recent clinical studies have demonstrated the safety and efficiency of adoptive immunotherapy for viral diseases, specifically, for EBV-associated LPD. Positron emission tomography (PET) with fluorodeoxyglucose (18F-FDG) is a method widely used to evaluate the response to antitumor therapy in patients with lymphomas; it seems to have certain advantages in assessing also the efficiency of T-cell therapy in patients with EBV-associated LPD and promote correction of this treatment. PET with 18F-FDG was performed in 17 patients with EBV-associated LPD on the stage of diagnosis and 14 days after injection of a dose of virus-specific cytotoxic T-lymphocytes, obtained by in vitro stimulation of peripheral mononuclear cells enriched with EBV-transformed recipient B-cells. Maximum standardized uptake value (SUVmax) was used for quantify assessment of the accumulation of 18F-FDG. Reduction of SUVmax in extracranial foci below 3 after a course of T-cell therapy in the absence of residual lesions indicated remission. The minimum residual disease, detected by PET with 18F-FDG (SUVmax above 5), indicated the need in a repeated therapeutic dose of T-cells till complete radiological effect were attained, correlating with clinical laboratory remission. The study on a small group of patients with EBV-associated LPD showed that PET with 18F-FDG could become an effective method for monitoring the response to T-cell immunotherapy, indicating the need and terms for repeated dose of T-cells.
Keywords: positron emission tomography; t-cell therapy; epstein-barr virus; epstein-barr virus-associated lymphoproliferative diseases; fluorodeoxyglucose (18f-fdg); maximum standardized uptake value (suvmax); post-transplant period
Journal Title: Voprosy Gematologii/Onkologii i Immunopatologii v Pediatrii
Volume: 13
Issue: 1
ISSN: 1726-1708
Publisher: Izdatel'stvo Dinastiya  
Date Published: 2014-01-01
Start Page: 32
End Page: 38
Language: Russian
PROVIDER: scopus
DOI/URL:
Notes: "Visualization of T-cell therapy efficiency by positron emission tomography in patients with Epstein-Barr virus-associated lymphoproliferative diseases" -- Article -- Export Date: 4 December 2017 -- Source: Scopus